These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 8729588

  • 1. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [Abstract] [Full Text] [Related]

  • 2. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E, Muratti EN, Eliav O, Peters TK.
    Am J Cardiol; 1995 Jul 13; 76(2):84A-88A. PubMed ID: 7604807
    [Abstract] [Full Text] [Related]

  • 4. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 13; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 5. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun 14; 153(11):1321-9. PubMed ID: 8507122
    [Abstract] [Full Text] [Related]

  • 6. The patient at risk: who should we be treating?
    Shviro I, Leitersdorf E.
    Br J Clin Pract Suppl; 1996 Jan 14; 77A():24-7. PubMed ID: 8729587
    [Abstract] [Full Text] [Related]

  • 7. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, Shichiri M, Sakai T, Kono S, Arakawa K.
    Int J Clin Pharmacol Ther; 1995 Jul 14; 33(7):420-6. PubMed ID: 7582401
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination.
    Leitersdorf E, Muratti EN, Eliav O, Meiner V, Eisenberg S, Dann EJ, Sehayek E, Peters TK, Stein Y.
    Am J Med; 1994 May 14; 96(5):401-7. PubMed ID: 8192170
    [Abstract] [Full Text] [Related]

  • 9. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr 14; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 10. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Apr 14; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 11. Development and pharmacology of fluvastatin.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1996 Jan 14; 77A():11-5. PubMed ID: 8729584
    [Abstract] [Full Text] [Related]

  • 12. Development and pharmacology of fluvastatin.
    Jokubaitis LA.
    Br J Clin Pract Suppl; 1994 Dec 14; (77):11-5. PubMed ID: 19489169
    [Abstract] [Full Text] [Related]

  • 13. The patient at risk: who should we be treating?
    Leitersdorf E.
    Br J Clin Pract Suppl; 1994 Dec 14; (77):24-7. PubMed ID: 19496269
    [Abstract] [Full Text] [Related]

  • 14. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
    Reyderman L, Kosoglou T, Cutler DL, Maxwell S, Statkevich P.
    Curr Med Res Opin; 2005 Aug 14; 21(8):1171-9. PubMed ID: 16083526
    [Abstract] [Full Text] [Related]

  • 15. Fluvastatin with and without niacin for hypercholesterolemia.
    Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF.
    Am J Cardiol; 1994 Jul 15; 74(2):149-54. PubMed ID: 8023779
    [Abstract] [Full Text] [Related]

  • 16. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM.
    J Am Coll Cardiol; 2008 Apr 22; 51(16):1564-72. PubMed ID: 18420099
    [Abstract] [Full Text] [Related]

  • 17. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
    Eliav O, Schurr D, Pfister P, Friedlander Y, Leitersdorf E.
    Am J Cardiol; 1995 Jul 13; 76(2):76A-79A. PubMed ID: 7604804
    [Abstract] [Full Text] [Related]

  • 18. Treatment of dyslipidaemias with fluvastatin.
    Peters TK.
    Br J Clin Pract Suppl; 1996 Jan 13; 77A():16-9. PubMed ID: 8729585
    [Abstract] [Full Text] [Related]

  • 19. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM, Ose L, Hagen E, Duriez P, Pfister P, Fruchart JC, Dallongeville J.
    Am J Cardiol; 1995 Jul 13; 76(2):65A-70A. PubMed ID: 7604802
    [Abstract] [Full Text] [Related]

  • 20. Treatment of dyslipidaemias with fluvastatin.
    Peters TK.
    Br J Clin Pract Suppl; 1994 Dec 13; (77):16-9. PubMed ID: 19514133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.